Mega Genomics Says Genetic Kits’ Share of Consumer Testing Revenue Falls to 21.4% in First Half

• Mega Genomics clarified ancillary services revenue totaled approximately RMB 109.8 million for the six months ended June 30, 2026.
• Testing materials generated a 28.6% gross margin, with equal margins on comparable sales to connected parties and independent customers.
• Genetic kits contributed 21.4% of consumer genetic testing revenue, down from 61.1% a year earlier.
• Marketing shifted back to on-site sample collection and testing in the third quarter of 2025; genetic kits are no longer a promotional priority.
• Expired genetic kit promoter agreements have not been renewed; promotional activities will move entirely in-house when remaining agreements expire.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mega Genomics Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261111-12408917), on November 11, 2026, and is solely responsible for the information contained therein.